Clicky

Arbutus Biopharma Corporation(ABUS)

Description: Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.


Keywords: Biopharmaceutical Infectious Diseases Alcohol Hydrogen Hepatitis B Gastrointestinal Lipid Metabolism Cholesterol Carcinoma Hepatocellular Carcinoma Liver Cancer Amyloidosis Hypercholesterolemia Acute Lymphoblastic Leukemia Interferon Ebola Amyloid Sexually Transmitted Diseases And Infections Hepatitis B Virus Neuroendocrine Tumors Zoonoses Rna Interference Transthyretin Pharmaceutical Partners Tlr9 Triglyceride Tropical Diseases Cyclophilin Neuroendocrine Tumor Transthyretin Amyloidosis PLK1 Biological Weapons

Home Page: www.arbutusbio.com

ABUS Technical Analysis

701 Veterans Circle
Warminster, PA 18974
United States
Phone: 267 469 0914


Officers

Name Title
Mr. William H. Collier Pres, CEO & Director
Mr. David C. Hastings CPA CFO & Chief Accounting Officer
Dr. Michael J. Sofia Ph.D. Chief Scientific Officer
Mr. Michael J. McElhaugh COO & Chief Bus. Officer
Ms. Lisa M. Caperelli VP of Investor Relations
Dr. Elizabeth Howard Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.
Dr. Gaston Picchio Ph.D. Chief Devel. Officer
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C. Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.8064
Price-to-Sales TTM: 11.6763
IPO Date: 2015-08-03
Fiscal Year End: December
Full Time Employees: 85
Back to stocks